Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA).
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The completion of this trial marks a key step forward for the company toward regulatory approval. Meanwhile, the company has also announced a series of important upcoming R&D milestones, indicating its continued progress in the field of AL amyloidosis treatment.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$80,648.06
+1.49%
Ethereum
ETH
$2,259.33
+0.05%
Tether USDt
USDT
$0.9996
+0.01%
BNB
BNB
$688.49
+2.27%
XRP
XRP
$1.47
+2.53%
USDC
USDC
$0.9996
-0.01%
Solana
SOL
$91.31
+0.37%
TRON
TRX
$0.3519
-0.75%
Dogecoin
DOGE
$0.1149
+1.19%
Hyperliquid
HYPE
$45.13
+15.61%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now